Amphastar Pharma (AMPH) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Amphastar Pharmaceuticals Reports Net Revenues of $53.9 Million for the Second Quarter Ended June 30, 2015
August 12, 2015 4:00 PM EDTRANCHO CUCAMONGA, Calif., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or the "Company") today reported results for the second quarter ended June 30, 2015.
Net revenues of $53.9 million for the second quarter GAAP net loss of $6.6 million, or $0.15 per diluted share for the second quarter Adjusted non-GAAP net loss of $3.9 million, or $0.09 per diluted share for the second quarter  Three Months Ended June 30, Six Months Ended June 30,  2015 2014 2015 2014  (in thousands, except per share data)... More